Discovery of a Series of Substituted 1 H -((1,2,3-Triazol-4-yl)methoxy)pyrimidines as Brain Penetrants and Potent GluN2B-Selective Negative Allosteric Modulators
Journal of Medicinal Chemistry · 23.02.2023 · 66 (4) · 2877-2892
DOI: 10.1021/acs.jmedchem.2c01916 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 09.02.2023. Verfasst von Christine F Gelin und 16 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Research & Development, 3210 Merryfield Row, San Diego, California 92121-1126, United States. Hauptthemen laut MEDLINE: Brain, Pyrimidines, Receptors, N-Methyl-D-Aspartate. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Herein, we describe a series of substituted 1H-((1,2,3-triazol-4-yl)methoxy)pyrimidines as potent GluN2B negative allosteric modulators. Exploration of several five- and six-membered heterocycles led to the identification of O-linked pyrimidine analogues that possessed a balance of potency and desirable ADME profiles. Due to initial observations of metabolic saturation, early metabolite identification studies were conducted on compound 18, and the results drove further iterative optimization efforts to avoid the formation of undesired saturating metabolites. The comprehensive investigation of substitution on the pyrimidine moiety of the 1H-1,2,3-triazol-4-yl)methoxy)pyrimidines allowed for the identification of compound 31, which demonstrated high GluN2B receptor affinity, improved solubility, and a clean cardiovascular profile. Compound 31 was profiled in an ex vivo target engagement study in rats at a 10 mg/kg oral dose and achieved an ED50 of 1.7 mg/kg.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Janssen Research & Development, 3210 Merryfield Row, San Diego, California 92121-1126, United States.
- Janssen Research & Development, Janssen-Cilag, S.A., Jarama 75A, 45007 Toledo, Spain.
ORCID-Profile: Christine F Gelin, Kevin J Coe, Kai Wang, Christa C Chrovian, Curt A Dvorak, Nicholas I Carruthers, Michael A Letavic
Zitieren
APA
Gelin, C. F., Stenne, B., Coate, H., Hiscox, A., Soyode-Johnson, A., Wall, J. L., Lord, B., Schoellerman, J., Coe, K. J., Wang, K., Alcázar, J., Chrovian, C. C., Dvorak, C. A., Carruthers, N. I., Koudriakova, T., Balana, B., & Letavic, M. A. (2023). Discovery of a Series of Substituted 1 H -((1,2,3-Triazol-4-yl)methoxy)pyrimidines as Brain Penetrants and Potent GluN2B-Selective Negative Allosteric Modulators. Journal of Medicinal Chemistry, 66(4), 2877-2892. https://doi.org/10.1021/acs.jmedchem.2c01916
Vancouver
Gelin CF, Stenne B, Coate H, Hiscox A, Soyode-Johnson A, Wall JL, et al. Discovery of a Series of Substituted 1 H -((1,2,3-Triazol-4-yl)methoxy)pyrimidines as Brain Penetrants and Potent GluN2B-Selective Negative Allosteric Modulators. Journal of Medicinal Chemistry. 2023;66(4):2877-2892. doi:10.1021/acs.jmedchem.2c01916
BibTeX
@article{Gelin2023,
author = {Gelin, Christine F and Stenne, Brice and Coate, Heather and Hiscox, Afton and Soyode-Johnson, Akinola and Wall, Jessica L and Lord, Brian and Schoellerman, Jeffrey and Coe, Kevin J and Wang, Kai and Alcázar, Jesus and Chrovian, Christa C and Dvorak, Curt A and Carruthers, Nicholas I and Koudriakova, Tatiana and Balana, Bartosz and Letavic, Michael A},
title = {Discovery of a Series of Substituted 1 H -((1,2,3-Triazol-4-yl)methoxy)pyrimidines as Brain Penetrants and Potent GluN2B-Selective Negative Allosteric Modulators},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {4},
pages = {2877--2892},
doi = {10.1021/acs.jmedchem.2c01916}
}
EUVIMED